CDK4 anticorps (Internal Region)
-
- Antigène Voir toutes CDK4 Anticorps
- CDK4 (Cyclin-Dependent Kinase 4 (CDK4))
-
Épitope
- Internal Region
-
Reactivité
- Humain, Souris, Rat
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp CDK4 est non-conjugé
-
Application
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
- Specificité
- CDK4 Antibody detects endogenous levels of total CDK4.
- Homologie
- Pig,Zebrafish,Bovine,Horse,Sheep,Rabbit,Dog,Xenopus
- Purification
- The antiserum was purified by peptide affinity chromatography using SulfoLinkTM Coupling Resin (Thermo Fisher Scientific).
- Immunogène
- A synthesized peptide derived from human CDK4, corresponding to a region within the internal amino acids.
- Isotype
- IgG
- Top Product
- Discover our top product CDK4 Anticorps primaire
-
-
- Indications d'application
- WB 1:500-1:2000, IHC 1:50-1:200, ELISA(peptide) 1:20000-1:40000
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- -20 °C
- Stockage commentaire
- Store at -20 °C. Stable for 12 months from date of receipt.
- Date de péremption
- 12 months
-
-
miR-3619-5p inhibits prostate cancer cell growth by activating CDKN1A expression." dans: Oncology reports, Vol. 37, Issue 1, pp. 241-248, (2017) (PubMed).
: "Targeted p53 activation by saRNA suppresses human bladder cancer cells growth and metastasis." dans: Journal of experimental & clinical cancer research : CR, Vol. 35, pp. 53, (2016) (PubMed).
: "
-
miR-3619-5p inhibits prostate cancer cell growth by activating CDKN1A expression." dans: Oncology reports, Vol. 37, Issue 1, pp. 241-248, (2017) (PubMed).
-
- Antigène
- CDK4 (Cyclin-Dependent Kinase 4 (CDK4))
- Autre désignation
- CDK4 (CDK4 Produits)
- Synonymes
- anticorps zgc:153726, anticorps CMM3, anticorps PSK-J3, anticorps Crk3, anticorps 8-6, anticorps CDK4, anticorps CDK4/6, anticorps CG5072, anticorps Cdk4/6, anticorps DmCdk4, anticorps Dmel\\CG5072, anticorps Pk53C, anticorps Pk?7, anticorps cdk, anticorps cdk4, anticorps cdk4/6, anticorps dCdk4, anticorps l(2)05428, anticorps l(2)0671, anticorps l(2)k06503, anticorps l(2)s4639, anticorps l(2)sh0671, anticorps xcdk4, anticorps cyclin-dependent kinase 4, anticorps cyclin dependent kinase 4, anticorps Cyclin-dependent kinase 4, anticorps cyclin-dependent kinase 4 L homeolog, anticorps cdk4, anticorps CDK4, anticorps Cdk4, anticorps cdk4.L
- Sujet
-
Description: Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G1 phase. Hypophosphorylates RB1 in early G1 phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.
Gene: CDK4
- Poids moléculaire
- 34kDa
- ID gène
- 1019
- UniProt
- P11802
- Pathways
- Cycle Cellulaire, Mitotic G1-G1/S Phases, Regulation of Cell Size
-